Diflucortolone


Concise Prescribing Info
Indications/Uses
Corticosteroid-responsive dermatoses.
Dosage/Direction for Use
Adult : Topical As 0.1% or 0.3% cream/oint: Apply thinly to the affected area bid. Max duration: 4 wk (0.1%); 2 wk (0.3%).
Dosage Details
Topical/Cutaneous
Corticosteroid-responsive dermatoses
Adult: As 0.1% or 0.3% cream/oint: Apply thinly to affected area bid, may reduce to once daily if condition improves. Max: 60 g wkly (0.3%). Max duration: 4 wk (0.1%); 2 wk (0.3%).
Child: 1-4 yr As 0.1% cream/oint: Apply thinly to affected area bid, may reduce to once daily if condition improves. Max duration: 5 days; ≥5 yr As 0.1% or 0.3% cream/oint: Apply thinly to affected area bid, may reduce to once daily if condition improves. Max duration: 1-2 wk; 5 days (face).
Contraindications
Acne vulgaris, undiagnosed perianal and genital pruritus, napkin eruptions, viral infections, untretated bacterial or fungal skin infections, post-vaccination skin reactions, rosacea, perioral dermatitis. Childn <5 yr (0.3% oint/cream).
Special Precautions
Patient w/ psoriasis, stasis dermatitis, leg ulcers. Prolonged use of occlusive dressings. Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Secondary infection, contact dermatitis. Rarely, adrenal suppression, Cushing’s syndrome.
Ophthalmologic: Glaucoma.
Dermatologic: Pruritus, irritation, erythema, burning, atrophy, striae, thinning, acneiform changes, hypertrichosis, telangiectasia, perioral dermatitis, discolouration, allergic skin reactions.
Patient Counseling Information
Avoid contact w/ the eyes.
MonitoringParameters
Monitor for hypothalamic-pituitary adrenal (HPA) axis suppression through ACTH stimulation test, plasma cortisol test, and urinary free cortisol test.
Action
Description: Diflucortolone is a glucocorticoid that has anti-inflammatory, antipruritic, and vasoconstrictive properties. It induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits the release of arachidonic acid, hence depresses the formation, release, and activity of endogenous chemical inflammatory mediators.
Pharmacokinetics:
Absorption: Absorbed percutaneously; may be absorbed systemically.
Metabolism: Metabolised in the liver.
Excretion: Via urine (75%) and faeces (25%). Elimination half-life: Approx 4-5 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Diflucortolone, CID=11954369, https://pubchem.ncbi.nlm.nih.gov/compound/Diflucortolone (accessed on Jan. 21, 2020)

Storage
Store between 15-25°C. Do not freeze.
ATC Classification
D07AC06 - diflucortolone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
References
Anon. Diflucortolone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 20/02/2017.

bioCSL NZ Ltd. Nerisone Cream and Fatty Ointment data sheet April 2013. Medsafe. http://www.medsafe.govt.nz/. Accessed 20/02/2017.

Buckingham R (ed). Diflucortolone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 20/02/2017.

Joint Formulary Committee. Diflucortolone Valerate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/02/2017.

Nerisone Cream (Meadow Laboratories Limited). MHRA. https://products.mhra.gov.uk/ . Accessed 20/02/2017.

Nerisone Forte Oily Cream (Meadow Laboratories Limited). MHRA. https://products.mhra.gov.uk/ . Accessed 20/02/2017.

Nerisone Forte Ointment (Meadow Laboratories Limited). MHRA. https://products.mhra.gov.uk/ . Accessed 20/02/2017.

Nerisone Oily Cream (Meadow Laboratories Limited). MHRA. https://products.mhra.gov.uk/ . Accessed 20/02/2017.

Nerisone Ointment (Meadow Laboratories Limited). MHRA. https://products.mhra.gov.uk/ . Accessed 20/02/2017.

Disclaimer: This information is independently developed by MIMS based on Diflucortolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in